Top 5 Drug Type | Count |
---|---|
Small molecule drug | 15 |
Diagnostic radiopharmaceuticals | 3 |
Synthetic peptide vaccine | 2 |
Therapeutic vaccine | 2 |
Contrast agent | 1 |
Mechanism ACVR2A modulators [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date26 Mar 2024 |
Target |
Mechanism FOLR1 agonists [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date29 Nov 2021 |
Target |
Mechanism HBV core protein inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Apr 2025 |
Sponsor / Collaborator ![]() [+1] |
Start Date01 Feb 2025 |
Sponsor / Collaborator ![]() [+4] |
Start Date01 Sep 2024 |
Sponsor / Collaborator ![]() [+1] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Sotatercept ( ACVR2A x activin receptor ) | Chronic Kidney Disease-Mineral and Bone Disorder More | Phase 2 |
Vebicorvir ( HBV core protein ) | Hepatitis B More | Phase 2 |
ABI-H2158 ( HBV core protein ) | Hepatitis B More | Phase 2 |
Allogeneic anti-CD4 CAR-T (Indiana University) ( CD4 ) | Acute Myeloid Leukemia More | Phase 2 |
MVF-HER-2 (597-626) Vaccine(Indiana University) | HER2 Positive Breast Cancer More | Phase 1 |